Morbidity of adjuvant high‐dose‐rate brachytherapy for low to intermediate risk endometrial adenocarcinoma completely resected

The aim of this retrospective analysis was to evaluate bowel and urinary acute and late morbidity in patients with low to intermediate risk endometrial carcinoma, submitted to total abdominal hysterectomy and bilateral salpingo‐oophorectomy, without lymphadenectomy, and postoperative high‐dose‐rate...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2001, Vol.96 (S1), p.105-108
Main Authors: Assis Pellizzon, Antonio Cassio, Fogarolli, Ricardo Cesar, Miziara, Miguel, Baraldi, Helena, Soares, Célia Regina
Format: Article
Language:English
Subjects:
Adenocarcinoma - mortality
Adenocarcinoma - radiotherapy
Biological and medical sciences
bowel morbidity
Brachytherapy - methods
Brachytherapy - mortality
Colon - radiation effects
cuff brachytherapy
Disease-Free Survival
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
endometrial cancer
Endometrial Neoplasms - mortality
Endometrial Neoplasms - radiotherapy
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
high‐dose‐rate brachytherapy
Humans
Medical sciences
Retrospective Studies
Time Factors
Tumors
urinary morbidity
Urinary Tract - radiation effects
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this retrospective analysis was to evaluate bowel and urinary acute and late morbidity in patients with low to intermediate risk endometrial carcinoma, submitted to total abdominal hysterectomy and bilateral salpingo‐oophorectomy, without lymphadenectomy, and postoperative high‐dose‐rate brachytherapy (HDR‐B) as the sole treatment. From March 1996 to June 1998, 70 patients were treated on an outpatient basis, to a total dose of 30–50 Gy, given in two fractions per week. A total of 4–5 fractions of 6–10 GY was delivered. Three patients (4.2%) developed severe bowel complications, with one patient experiencing severe rectal bleeding. Local control was observed in 68 (97.1%) patients. Five‐year actuarial disease and complication‐free survival were 94.3% and 96.8%, respectively. In conclusion, it seems that a modest dose fraction schedule of HDR‐B yields very high local control rates and low morbidity rates. © 2002 Wiley‐Liss, Inc.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.10356